Scilex Holding Co
SCLX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$2.35
KIRA · Stoqly’s AI analyst, in plain words
- Scilex Holding Co had $30.3M of revenue in fiscal 2025, down 46.5% on the year before. Over five years, revenue changed +5.1% a year on average.
- Its operating margin was −1,143.7%, down 996.3 pts: of every 100 in sales, about −1,144 is left after running the business.
- Scilex Holding Co lost $374M in fiscal 2025.
- Free cash flow was $3.7M in fiscal 2025, 12.2% of revenue.
- Scilex Holding Co owes $78.3M more than it holds in cash.
Market cap
$16.2M
P/E
—
Revenue
$30.3M
Net income
−$374M
Free cash flow
$3.7M
Operating margin
−1,143.7%
Scilex Holding Co in 30 seconds · fiscal 2025
Are sales growing?
−46.5%
No. Sales fell 46.5% last year.
Does it make a profit?
−1,236.4%
No. It lost money last year.
Does profit turn into cash?
12.2%
Yes. 12.2% of sales ends up as free cash.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Scilex Holding Co does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 10, 2026
- Legal name
- Scilex Holding Co
- CIK
- 0001820190
Scilex Holding Co · SCLX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $31.3M | $38.0M | $46.7M | $56.6M | $30.3M |
| Revenue growth | 32.9% | 21.4% | 22.9% | 21.1% | −46.5% |
| Gross margin | 88.4% | 71.6% | 66.5% | 295.8% | 415.8% |
| Operating margin | −114.4% | −133.1% | −225.6% | −147.4% | −1,143.7% |
| Net income | −$88.4M | −$23.4M | −$114M | −$72.8M | −$374M |
| Net margin | −282.4% | −61.4% | −244.6% | −128.7% | −1,236.4% |
| Diluted EPS | −$0.67 | −$0.17 | −$1.28 | −$8.05 | −$36.48 |
| Cash | |||||
| Cash from operations | −$28.7M | −$21.3M | −$20.7M | $19.3M | $3.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$28.7M | −$21.3M | −$20.7M | $19.3M | $3.7M |
| FCF margin | −91.5% | −55.9% | −44.4% | 34.2% | 12.2% |
| Dividends paid | — | — | $8.7M | $8.7M | — |
| Share count change | 99,868.4% | 1.0% | −2.9% | −100.0% | 8.9% |
| Debt and strength | |||||
| Cash and short-term investments | $4.6M | $2.2M | $3.9M | $3.3M | $5.0M |
| Debt incl. finance leases | $110M | $0.0M | $108M | $34.9M | $83.3M |
| Shareholders' equity | −$224M | $36.2M | −$173M | −$193M | −$208M |
| Current ratio | 0.1x | 0.7x | 0.2x | 0.2x | 0.1x |
| Interest coverage | −3.0x | −5.3x | −98.7x | −42.5x | −30.2x |
| Returns and quality | |||||
| Return on capital | — | −117.5% | — | — | — |
| Piotroski F-score | 2 | 5 | 3 | 7 | 4 |
| Altman Z'' | −30.9 | −18.5 | −36.6 | −41.9 | −23.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$12.8M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Scilex Holding Co · SCLX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.35 a share, the company is worth $16.2M.
Source: SEC EDGAR XBRL filings (CIK 0001820190). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.